Trademark: 85482864
Status Date
Monday, February 1, 2016
Filing Date
Tuesday, November 29, 2011
Published for Opposition
Tuesday, October 30, 2012
Abandoned Date
Monday, February 1, 2016
1 Chemicals, biochemicals and reagents for use in industry and science; Chemicals for use in biochemical and chemical industry; chemicals for use in agriculture; chemicals for use in biotechnological product development; chemicals for use in biotechnological manufacturing processes; chemical preparations for scientific purposes; chemical reagents for non-medical purposes; chemicals, biochemicals and reagents, namely, proteins for regulating, modifying or restricting cellular activity or gene expression, ligands, genetic vectors, genetic hosts, genetic biochemicals, genetic bioengineering reagents and proteins for use in modifying and regulating cellular functions in transgenic plants, fungi and animals, and in cells of plants, fungi and animals; antibodies for scientific and research use; antibodies for regulating, modifying or regulating cellular functions in plants, fungi and animals, and in cells of plants, fungi and animals; kits consisting primarily of proteins for regulating, modifying or restricting cellular activity or gene expression; Research reagents for pharmaceutical discovery or disease research, drug discovery or drug development; Chemical inducers of gene expression in plants, mammals, fungi and bacteria for industrial and agricultural applications; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof
5 Chemical preparations for medical and veterinary purposes, namely, chemical preparations for regulating, modifying, or restricting cellular activity or gene expression for purposes of treating diseases and genetic disorders; chemical preparations for antibody therapy, for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for therapeutic analysis; biochemical preparations for medical and veterinary purposes, namely, biochemical preparations for antibody therapy, for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for antibody therapy analysis; Pharmaceutical preparations for modifying or regulating one or more cellular functions of mammals, fungi, plants, and bacteria and transgenic mammals, fungi, plants, and bacteria; transgenic plants, fungi and bacteria for medical and veterinary purposes; antibodies for use in disease testing; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof
40 Custom manufacturing and custom synthesis of antibodies and genetically engineered DNA expressing antibodies, biological organisms, cells, viruses, pathogens and special purpose cells to the specifications of others for scientific, research, medical, veterinary and laboratory use; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof
42 Development of new technology for others in the field of genetics, therapeutics and biotechnology; Development of products being antibodies and genetic therapies expressing antibodies to regulate, modulate, treat, prevent, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the fields of biotechnology and antibody technology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells expressing antibodies for scientific, research, medical, veterinary and laboratory use; Scientific research and product development services for others in the pharmaceutical, biotechnology, biosensors, bioelectronics, medical and agriculture fields; Antibody technology and gene therapy services for others for product development and scientific research purposes, namely, antibody production, genetically engineering DNA expressing antibodies, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical, veterinary and laboratory use; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof
44 Medical services; Medical services, namely, antibody and gene therapy services; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof
45 Technology transfer services, namely, licensing and transfer of intellectual property; all of the foregoing featuring, including or involving monoclonal antibodies or portions thereof
Color is not claimed as a feature of the mark.
"MAB"
Feb 1, 2016
Abandonment Notice Mailed - No Use Statement Filed
Feb 1, 2016
Abandonment - No Use Statement Filed
Jul 9, 2015
Notice Of Approval Of Extension Request E-Mailed
Jul 8, 2015
Extension 5 Granted
Jun 23, 2015
Extension 5 Filed
Jun 23, 2015
Teas Extension Received
Dec 16, 2014
Notice Of Approval Of Extension Request E-Mailed
Dec 15, 2014
Extension 4 Granted
Dec 11, 2014
Extension 4 Filed
Dec 11, 2014
Teas Extension Received
Jun 3, 2014
Notice Of Approval Of Extension Request E-Mailed
Jun 2, 2014
Extension 3 Granted
May 28, 2014
Extension 3 Filed
May 28, 2014
Teas Extension Received
Jan 31, 2014
Notice Of Approval Of Extension Request E-Mailed
Jan 30, 2014
Extension 2 Granted
Dec 4, 2013
Extension 2 Filed
Jan 24, 2014
Case Assigned To Intent To Use Paralegal
Jan 24, 2014
Case Assigned To Intent To Use Paralegal
Dec 4, 2013
Teas Extension Received
Jun 20, 2013
Notice Of Approval Of Extension Request E-Mailed
Jun 18, 2013
Extension 1 Granted
Jun 18, 2013
Extension 1 Filed
Jun 18, 2013
Teas Extension Received
Dec 25, 2012
Noa E-Mailed - Sou Required From Applicant
Oct 30, 2012
Official Gazette Publication Confirmation E-Mailed
Oct 30, 2012
Published For Opposition
Oct 10, 2012
Notification Of Notice Of Publication E-Mailed
Sep 21, 2012
Law Office Publication Review Completed
Sep 20, 2012
Approved For Pub - Principal Register
Sep 20, 2012
Examiner's Amendment Entered
Sep 20, 2012
Notification Of Examiners Amendment E-Mailed
Sep 20, 2012
Examiners Amendment E-Mailed
Sep 20, 2012
Examiners Amendment -Written
Sep 7, 2012
Notification Of Non-Final Action E-Mailed
Sep 7, 2012
Non-Final Action E-Mailed
Sep 7, 2012
Non-Final Action Written
Sep 4, 2012
Previous Allowance Count Withdrawn
Aug 26, 2012
Withdrawn From Pub - Og Review Query
Aug 10, 2012
Law Office Publication Review Completed
Aug 10, 2012
Assigned To Lie
Jul 27, 2012
Approved For Pub - Principal Register
Jul 27, 2012
Examiner's Amendment Entered
Jul 27, 2012
Notification Of Examiners Amendment E-Mailed
Jul 27, 2012
Examiners Amendment E-Mailed
Jul 27, 2012
Examiners Amendment -Written
Jul 20, 2012
Teas/Email Correspondence Entered
Jul 19, 2012
Correspondence Received In Law Office
Jul 19, 2012
Teas Response To Office Action Received
Mar 14, 2012
Notification Of Non-Final Action E-Mailed
Mar 14, 2012
Non-Final Action E-Mailed
Mar 14, 2012
Non-Final Action Written
Mar 12, 2012
Assigned To Examiner
Dec 5, 2011
New Application Office Supplied Data Entered In Tram
Dec 2, 2011
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
